title: Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer.
abstract: The relation between cancer and coagulation is the subject of investigation since a relation between tumor and thrombosis has been determined. Antithrombin III is an important thrombin inhibitor, and increased thrombin-antithrombin (TAT) complex levels activate coagulation. Activated thrombin activatable fibrinolysis inhibitor (TAFI) inhibits the conversion of plasminogen to plasmin. In addition, it directly inactivates plasmin. Defective fibrinolysis increases the risk of thrombosis. In this study, we evaluated homeostatic parameters, TAFI, and TAT levels in patients with gastric cancer applying to the medical oncology outpatient clinic. Fifty-two patients and 35 healthy controls were included. ELISA was used to measure TAFI and TAT complex levels. These were statistically higher in the patient group (p < 0.05 and p = 0.001, respectively). D-dimer levels were higher in stage IV (p = 0.05). Correlations between lymph nodes and TAFI and TAT levels were examined. Weak but positive correlation between lymph nodes and TAFI was detected (R = 0.452, p = 0.027). TAFI and TAT levels were evaluated using relative operating characteristic analysis to differentiate the disease. TAT was more specific than TAFI according to this analysis (TAFI area under curve (AUC), 0.676; TAT AUC, 0.874). Thrombotic events and bleeding disorders need to be borne in mind in gastric cancer. This situation is due to the impairment of the balance between coagulation and fibrinolysis. Further studies are now needed to evaluate the effects of TAFI and TAT on survey and prognosis as well as the potential of these parameters as tumor markers for gastric cancer.
authors.affiliation: Division of Medical Oncology, School of Medicine, Karadeniz Technical University, 61080, Trabzon, Turkey. evrenfidan@yahoo.com
authors.forename: Evren
authors.initials: E
authors.lastname: Fidan
authors.forename: Halil
authors.initials: H
authors.lastname: Kavgaci
authors.forename: Asim
authors.initials: A
authors.lastname: Orem
authors.forename: Mustafa
authors.initials: M
authors.lastname: Yilmaz
authors.forename: Bulent
authors.initials: B
authors.lastname: Yildiz
authors.forename: Sami
authors.initials: S
authors.lastname: Fidan
authors.forename: Buket
authors.initials: B
authors.lastname: Akcan
authors.forename: Feyyaz
authors.initials: F
authors.lastname: Ozdemir
authors.forename: Fazil
authors.initials: F
authors.lastname: Aydin
mesh_terms: D000328:Adult; D000368:Aged; D000990:Antithrombin III / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000097:blood; D025901:Carboxypeptidase B2 / Q000097:blood / Q000378:metabolism*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012372:ROC Curve; D013274:Stomach Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D013917:Thrombin / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D000990:Antithrombin III; D025901:Carboxypeptidase B2; D013917:Thrombin